MIAMI - nvtip -- RevGenetics is disrupting the metabolic support market today with the commercial launch of DiBerberine 300x, an advanced enteric-coated dihydroberberine (DHB) supplement. By directly addressing the industry-wide "berberine absorption gap," RevGenetics exposes a flaw found in nearly every major competing brand: the failure to protect the active compound from stomach acid degradation and P-glycoprotein (P-gp) efflux pumps.

"The question we kept asking was: why is the supplement industry selling a mechanism - AMPK activation - with a delivery system that undermines the mechanism?" said RevGenetics founder Anthony Loera. "Most every major brand in the berberine category is selling a standard vegetarian capsule with berberine. Nobody in the supplement industry was solving them in a single product."

More on nvtip.com

• Charging Into the $30 Billion Heart Failure Market with Late-Stage Momentum, Breakthrough Data, & Strong Financial Backing: Cardiol Therapeutics $CRDL
• All American Home Renovators: Transforming Bathrooms into Masterpieces, One Home at a Time
• MGM Resorts International Appoints Grant Michael Leingang to Lead Intellectual Property
• Bold Beauty Project Celebrates Anniversary with Collaborative Exhibition at FIU's Miami Beach Urban Studios
• Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation

Unlike standard formulas, The DiBerberine 300x Triple-Action Protocol sets a new standard by combining:

• Enteric Capsule Technology: Borrowing from pharmaceutical methods, this acid-resistant capsule bypasses the stomach without dissolving, preventing DHB from reverting to standard berberine HCl and ensuring release in the small intestine.
• DiBerberine™ Proprietary Blend (500mg per capsule): This leverages the profound pharmacokinetic advantage of DHB. A 2022 study showed a 100mg dose yielded ~6.7x greater plasma exposure than 500mg of standard berberine HCl.
• RGBooster1™: A patent-pending (U.S. App. No. 63/837,080) flavonoid complex. Internal assays demonstrate our Sophora japonica extract is up to 300x more potent than piperine at modulating the P-gp active transport mechanism that expels compounds from intestinal cells.

"Enteric coating isn't new technology," Loera stated. "Applying that technology to DHB was the obvious move. It just hadn't been done in a commercially available formula."

More on nvtip.com

• Bold Beauty Project Announces Exhibition at Palazzo Mora Venice, Italy
• Financial Educator Jessica Perrone Launches Free "3 Stages of Building Wealth" Course for Women
• Captain Notepad Expands Free Custom Design Services Across Full Product Line
• Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
• Phinge Corporation Home of Netverse, Announces Exploration of Potential Merger With Nasdaq or NYSE-Listed Special Purpose Acquisition Company (SPAC)

Manufactured in the USA in a cGMP-certified, third-party tested facility, DiBerberine 300x is now available at revgenetics.com. A 30-day supply (30 enteric capsules) is priced at $44.95.

Health and wellness influencers, practitioners, and marketers interested in partnering with RevGenetics for this launch can access the affiliate program at getlink.revgenetics.com.